详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors.

119| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Hematology, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital,University of Electronic Science and Technology of China, Chengdu, China, [2]Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China & Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China & Key Laboratory of Bone Marrow Stem Cell, Xuzhou, China, [3]Department of Gastroenterology, The Second Affiliated Hospital of Chengdu Medical College, Nuclear Industry 416 Hospital, Chengdu, China, [4]School of Bioscience and Technology, Chengdu Medical College, Chengdu, China

出处：

DOI：

ISSN：

关键词： colorectal cancer ICB resistance m6A epigenetics overcome resistance

摘要：

Tumor immunotherapy, one of the efficient therapies in cancers, has been called to the scientific community's increasing attention lately. Among them, immune checkpoint inhibitors, providing entirely new modalities to treat cancer by leveraging the patient's immune system. They are first-line treatments for varieties of advanced malignancy, such as melanoma, gastrointestinal tumor, esophageal cancer. Although immune checkpoint inhibitors (ICIs) treatment has been successful in different cancers, drug resistance and relapses are common, such as in colorectal cancer. Therefore, it is necessary to improve the efficacy of immune checkpoint therapy for cancer patients who do not respond or lowly response to current treatments. N6-methyladenosine (m6A), as a critical regulator of transcript expression, is the most frequently internal modification of mRNA in the human body. Recently, it has been proposed that m6A epigenetic modification is a potential driver of tumor drug resistance. In this report, we will briefly outline the relevant mechanisms, general treatment status of immune checkpoint inhibitors in colorectal cancer, how m6A epigenetic modifications regulate the response of ICIs in CRC and provide new strategies for overcoming the resistance of ICIs in CRC.Copyright © 2022 Tong, Wei, Smith and Huang.

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 2 区

医学

小类 | 2 区免疫学

最新[2023]版：

大类 | 2 区医学

小类 | 2 区免疫学

JCR分区：

出版当年[2022]版：

Q1 IMMUNOLOGY

最新[2023]版：

Q1 IMMUNOLOGY

影响因子： 5.7 最新[2023版] 6.8 最新五年平均 7.3 出版当年[2022版] 8 出版当年五年平均 8.787 出版前一年[2021版] 5.7 出版后一年[2023版]

第一作者：

第一作者机构： [1]Department of Hematology, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital,University of Electronic Science and Technology of China, Chengdu, China, [2]Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China & Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China & Key Laboratory of Bone Marrow Stem Cell, Xuzhou, China,

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors.

文献详情

相关文献